Hudson Bay Capital Management
SLNO

Hudson Bay Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Hudson Bay Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-150,000
Closed -$10.1M – 1499
2025
Q3 		$10.1M Buy
150,000
+125,000
+500% +$9.27M 0.03% 353
2025
Q2 		$2.09M Buy
+25,000
New +$1.87M 0.01% 784

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Hudson Bay Capital Management's SLNO Position: Q1 2026 in Review

Hudson Bay Capital Management increased its Soleno Therapeutics (SLNO) stake by 59,868% in Q1 2026, buying an estimated $7.96M and bringing the position to 203,291 shares worth $6.81M. The position accounts for 0.02% of the portfolio, ranked #405.

Hudson Bay Capital Management first reported a position in SLNO in Q4 2014 and has held it in 7 quarters since. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Hudson Bay Capital Management held 203,291 shares of Soleno Therapeutics worth $6.81M as of Q1 2026.
  • Hudson Bay Capital Management bought 202,952 Soleno Therapeutics shares in Q1 2026, an estimated $7.96M.
  • Soleno Therapeutics made up 0.02% of Hudson Bay Capital Management's portfolio in Q1 2026, its #405 holding.
  • Hudson Bay Capital Management first reported a position in Soleno Therapeutics in Q4 2014 and has held it in 7 quarters since.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.